Corvus Pharmaceuticals has been granted a patent for methods and compounds that modulate Interleukin-2-inducible T-cell kinase. The patent includes a specific compound of Formula (IIA). GlobalData’s report on Corvus Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Corvus Pharmaceuticals Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Corvus Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Corvus Pharmaceuticals's grant share as of February 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11897874B2) discloses a compound of Formula (IIA) and various derivatives with specific substituents, including hydrogen, halogen, alkyl, and heteroalkyl groups. The patent also covers pharmaceutical compositions comprising the compound and methods for treating T-cell lymphoma, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma, by administering the disclosed compound or composition to patients in need.

The patent further extends to methods of treating T-cell lymphoma using specific compounds with defined structures and pharmaceutical compositions containing these compounds. The disclosed methods aim to provide effective treatment for T-cell lymphoma, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma, with unspecified subtypes. By administering the compound or composition as described in the patent, the disclosed methods offer a targeted approach to addressing T-cell lymphoma in patients, potentially improving outcomes for individuals suffering from these conditions.

To know more about GlobalData’s detailed insights on Corvus Pharmaceuticals, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies